UroGen Pharma Ownership | Who Owns UroGen Pharma?
UroGen Pharma Ownership Summary
UroGen Pharma is owned by 37.99% institutional investors, 3.90% insiders, and 58.11% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 9.52% of URGN shares. BioPharma Credit Ord is the top mutual fund, with 10.18% of its assets in UroGen Pharma shares.
URGN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | UroGen Pharma | 37.99% | 3.90% | 58.11% |
| Sector | Healthcare Stocks | 232.01% | 10.74% | -142.75% |
| Industry | Biotech Stocks | 381.47% | 10.55% | -292.02% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Rtw investments, lp | 4.54M | 9.52% | $90.65M |
| Paradigm biocapital advisors lp | 4.22M | 8.83% | $84.11M |
| Toronto dominion bank | 3.19M | 6.68% | $63.65M |
| Blackrock | 2.19M | 6.57% | $36.81M |
| Cowen and company | 2.10M | 6.29% | $35.23M |
| Blackrock funding, inc. /de | 2.60M | 5.41% | $60.92M |
| Morgan stanley | 2.56M | 5.33% | $60.02M |
| Jefferies financial group | 2.20M | 4.58% | $51.52M |
| Silverarc capital management | 1.74M | 3.62% | $40.72M |
| Sg americas securities | 1.38M | 2.87% | $32.26M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Acorn capital advisors | 1.26M | 12.76% | $25.13M |
| Silverarc capital management | 1.74M | 5.66% | $40.72M |
| Boxer capital management | 575.00K | 3.66% | $11.47M |
| Paradigm biocapital advisors lp | 4.22M | 2.39% | $84.11M |
| Superstring capital management lp | 87.91K | 1.73% | $1.75M |
| Rtw investments, lp | 4.54M | 1.12% | $90.65M |
| Cowen and company | 2.10M | 0.97% | $35.23M |
| Privium fund management b.v. | 214.62K | 0.93% | $5.03M |
| Parkman healthcare partners | 402.60K | 0.84% | $8.03M |
| Tang capital management | 1.00M | 0.77% | $19.95M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | 4.22M | 2.39% | 4.22M |
| Tcg crossover management | 717.35K | 0.70% | 717.35K |
| Voloridge investment management | 687.48K | 0.05% | 687.48K |
| Blackrock | 2.19M | 0.00% | 477.14K |
| Cowen and company | 2.10M | 0.97% | 472.89K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ra capital management | - | - | -3.21M |
| Vestal point capital, lp | - | - | -2.15M |
| Millennium management | 645.78K | 0.00% | -853.42K |
| Adage capital partners gp | - | - | -830.00K |
| Rosalind advisors | - | - | -542.37K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Paradigm biocapital advisors lp | 4.22M | 2.39% | 4.22M | $84.11M |
| Tcg crossover management | 717.35K | 0.70% | 717.35K | $14.31M |
| Voloridge investment management | 687.48K | 0.05% | 687.48K | $13.72M |
| Eam investors | 160.41K | 0.42% | 160.41K | $3.76M |
| Bioimpact capital | 135.00K | 0.44% | 135.00K | $2.69M |
Sold Out
| Holder | Change |
|---|---|
| Twin peaks wealth advisors | -2.00 |
| Nelson, van denburg & campbell wealth management group | -4.00 |
| Clearstead advisors | -9.00 |
| Coldstream capital management | -29.00 |
| Systm wealth solutions | -48.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 99 | -42.11% | 18,257,389 | -58.48% | 37 | 0.45% | 43 | -49.41% | 32 | -30.43% |
| Sep 30, 2025 | 162 | 4.52% | 41,959,889 | 15.94% | 87 | 1.53% | 82 | 2.50% | 45 | 7.14% |
| Jun 30, 2025 | 163 | 13.99% | 39,787,671 | -4.46% | 83 | 1.08% | 84 | 31.25% | 43 | -12.24% |
| Mar 31, 2025 | 143 | 2.14% | 41,643,982 | 14.80% | 87 | 1.24% | 64 | -11.11% | 49 | 25.64% |
| Dec 31, 2024 | 101 | -23.48% | 19,804,522 | -43.62% | 45 | 0.69% | 52 | -30.67% | 26 | -13.33% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BioPharma Credit Ord | 4.69M | 10.18% | 4.69M |
| RTW Biotech Opportunities Ord | 1.36M | 2.90% | 1.36M |
| UBS (Lux) Digital Health Equity SB USD | 1.32M | 2.86% | - |
| UBS Lux Dgtl Hlth Eq Fd seeding P acc | 1.25M | 2.71% | - |
| iShares Russell 2000 ETF | 892.82K | 1.91% | 892.82K |
| American Century Small Cap Growth Inv | 653.04K | 1.40% | 653.04K |
| American Century U.S. Small Cap Growth | 653.04K | 1.40% | 653.04K |
| Biotech Growth Ord | 582.00K | 1.24% | -209.90K |
| T. Rowe Price Health Sciences | 459.06K | 0.98% | 12.02K |
| International Biotechnology Ord | 427.15K | 0.93% | -34.85K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 03, 2026 | Smith Jason Drew | General Counsel | Sell | $31.66K |
| Feb 03, 2026 | Smith Jason Drew | General Counsel | Sell | $52.26K |
| Feb 03, 2026 | Smith Jason Drew | General Counsel | Sell | $63.34K |
| Feb 03, 2026 | Schoenberg Mark | Chief Medical Officer | Sell | $36.31K |
| Feb 03, 2026 | Schoenberg Mark | Chief Medical Officer | Sell | $72.58K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 3 |
| 2025 Q4 | - | 2 |
| 2025 Q3 | - | 5 |
| 2025 Q2 | - | 1 |
| 2025 Q1 | - | 6 |
URGN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools